Two therapies "could slow diabetic retinopathy progression"

Two therapies "could slow diabetic retinopathy progression"

A combination of two therapies could slow the progression of diabetic retinopathy in high-risk adults with type 2 diabetes, a recent study has suggested.

This eye disease is the leading cause of vision loss in working-age Americans, so such a development could have a huge impact on the lives of a great number of people.

Results of the Action to Control Cardiovascular Risk in Diabetes (Accord) Eye Study, supported by the National Institutes of Health, were published online recently in the New England Journal of Medicine.

"The Accord Eye Study clearly indicates that intensive glycemic control and fibrate treatment added to statin therapy separately reduce the progression of diabetic retinopathy," said Dr Emily Chew, chair of the research.

She went on to explain that the research"s main findings indicate that fibrate treatment plus statin therapy is safe for patients.

According to the NHS, 25 per cent of people who have type 2 diabetes but do not require insulin have some degree of diabetic retinopathy five years after the onset of symptoms.

by Alexa Kaczka

« Back to list